NEW YORK CITY (dpa-AFX) - Biotech company I-Mab (IMAB) announced Wednesday
that it has entered into a clinical trial collaboration and supply agreement
with Bristol Myers Squibb (BMY).

The collaboration will evaluate the combination of givastomig, an
investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by
I-Mab and ABL Bio, with Bristol Myers Squibb's immune checkpoint inhibitor,
nivolumab, and chemotherapy (FOLFOX or CAPOX), as a potential first-line
treatment for patients with advanced Claudin 18.2-positive gastric and
esophageal cancers.

Under the terms of the agreement, the study will be a multi-national Phase 1
study conducted by I-Mab. Bristol Myers Squibb will supply nivolumab.

Nivolumab is an immune checkpoint inhibitor that is designed to block the PD-L1
protein on cancer cells from binding to PD-1, enhancing T-cell function and
resulting in improved anti-tumor responses.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX